Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
NCT ID: NCT07170046
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-09-15
2027-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
NCT02647164
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NCT06262386
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
NCT03710616
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
NCT03465241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
retrospective cohort
The clinical information of the population in this cohort was retrospectively collected.
No interventions assigned to this group
prospective cohort
The clinical information of the population in this cohort was prospectively collected.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. MRD testing was conducted before the operation
3. The primary lesion was resected through surgery
4. There should be at least two CEA and MRD follow-up tests within 2 years after the operation
5. Postoperative pathology confirmed it as a malignant lung tumor
Exclusion Criteria
2. Patients with a history of malignant tumors within the past five years
3. Patients with secondary lung cancer
15 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY2025-310
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.